1.Hepatocarcinogenesis in liver cirrhosis: imaging diagnosis.
Journal of Korean Medical Science 1998;13(2):103-116
Hepatocellular carcinoma (HCC) frequently occurs in association with liver cirrhosis, as chronic liver disease is one of the most important factors in carcinogenesis. In addition to HCCs, recent reports of pathologic studies of resected specimens from cirrhotic liver describe associated small nodular lesions such as regenerative nodule, dysplastic nodule (adenomatous hyperplasia), and dysplastic nodule with subfocus of HCC (early HCC). In hepatocarcinogenesis of the cirrhotic liver, a regenerative nodule might be the first step in the development of HCC, going through phases of dysplastic nodule, early HCC and early advanced HCC in a multistep fashion. Fortunately, recent advances in various imaging techniques have facilitated the verification of these nodules. In this review, new nomenclature of small hepatocellular nodules, and detection and characterization of hepatic nodules in carcinogenesis with various imaging techniques are described with focus on the premalignant lesions and early stage of HCC. In addition, the efficacy of various imaging techniques for diagnosing them is discussed. Although the terms and definitions of these nodules are still variable and controversial, familiarity with the concept of these borderline lesions is important.
Carcinoma, Hepatocellular/pathology
;
Carcinoma, Hepatocellular/diagnosis*
;
Carcinoma, Hepatocellular/complications
;
Diagnostic Imaging*/methods
;
Human
;
Liver Cirrhosis/pathology
;
Liver Cirrhosis/diagnosis*
;
Liver Cirrhosis/complications
;
Patient Care Management
;
Terminology
3.Comparative effectiveness of different hepatocellular carcinoma screening intervals or modalities: a systematic review and meta-analysis.
Jichun YANG ; Zhirong YANG ; Xueyang ZENG ; Shuqing YU ; Le GAO ; Yu JIANG ; Feng SUN
Chinese Medical Journal 2023;136(11):1322-1330
BACKGROUND:
Current guidelines recommend hepatocellular carcinoma (HCC) screening in high-risk populations. However, the ideal HCC screening interval and screening modality have not been determined. This study aimed to compare the screening efficacy among different modalities with various intervals.
METHODS:
PubMed and other nine databases were searched through June 30, 2021. Binary outcomes were pooled using risk ratio (RR) with 95% confidence intervals (CIs). Survival rates were also pooled using RR with 95% CIs because most eligible studies only provided the number of survival patients instead of hazard ratio.
RESULTS:
In all, 13 studies were included. Two random controlled trials (RCTs) and six cohort studies compared screening intervals for ultrasonography (US) screening and found no significant differences between shorter (3- or 4-month) and longer (6- or 12-month) screening intervals in terms of early HCC proportion, HCC significant mortality, 1-year survival rate; screening at 6-month interval significantly increased the proportion of early HCC (RR = 1.17, 95% confidence interval [CI]: 1.08-1.26) and prolonged the 5-year survival rate (RR = 1.39, 95% CI: 1.07-1.82) relative to the 12-month interval results. Three other RCTs and two cohort studies compared different screening modalities in cirrhosis or chronic hepatitis B, which indicated no statistical differences in the proportion of early HCC (RR = 0.89, 95% CI: 0.40-1.96) and HCC mortality (RR = 0.69, 95% CI: 0.23-2.09) between the biannual US and annual computed tomography (CT screening). Biannual US screening showed a lower proportion of early HCC than biannual magnetic resonance imaging (MRI) (RR = 0.60, 95% CI: 0.37-0.97) and biannual US combined with annual CT (RR = 1.31, 95% CI: 1.13-1.51) screening. The proportion of early HCC in the contrast-enhanced US group was slightly higher than that in the B-mode US (RR = 1.08, 95% CI: 1.00-1.23) group.
CONCLUSIONS:
The evidence suggests that 6 months may be the best HCC screening interval for US screening. The effectiveness of CT and MRI is better than US during same screening intervals. However, MRI and CT are more expensive than US, and CT also can increase the risk of radiation exposure. The selection of CT or MRI instead of US should be carefully considered.
REGISTRATION
No. CRD42020148258 at PROSPERO website ( https://www.crd.york.ac.uk/PROSPERO/ ).
Humans
;
Carcinoma, Hepatocellular/pathology*
;
Liver Neoplasms/pathology*
;
Liver Cirrhosis/complications*
;
Risk Factors
;
Cohort Studies
5.Current status of laparoscopic liver resection for hepatocellular carcinoma.
Hanisah GURO ; Jai Young CHO ; Ho Seong HAN ; Yoo Seok YOON ; YoungRok CHOI ; Mohan PERIYASAMY
Clinical and Molecular Hepatology 2016;22(2):212-218
Laparoscopic liver resection (LLR) is becoming widely accepted for the treatment of hepatocellular carcinoma (HCC). Laparoscopic left lateral sectionectomy and minor laparoscopic liver resection are now considered standard approaches, especially for tumors located in the anterolateral segments of the liver. Laparoscopic left lateral sectionectomy in adult donors is also gaining acceptance for child liver transplantation in many centers. Major LLRs, including left hepatectomy and right hepatectomy, have been recently attempted. Laparoscopic donor hepatectomy is becoming more popular owing to increasing demand from young living donors who appreciate its minimal invasiveness and excellent cosmetic outcomes. Several centers have performed total laparoscopic donor right hepatectomy in adult-to-adult living donor liver transplantation. Many meta-analyses have shown that LLR is better than open liver resection in terms of short-term outcomes, principally cosmetic outcomes. Although no randomized control trials have compared LLR with open liver resection, the long-term oncologic outcomes were similar for both procedures in recent case-matched studies.
Carcinoma, Hepatocellular/complications/pathology/*surgery
;
Humans
;
Laparoscopy
;
Liver Cirrhosis/complications
;
Liver Neoplasms/pathology/*surgery
;
Neoplasm Recurrence, Local
;
Prognosis
6.Current status of laparoscopic liver resection for hepatocellular carcinoma.
Hanisah GURO ; Jai Young CHO ; Ho Seong HAN ; Yoo Seok YOON ; YoungRok CHOI ; Mohan PERIYASAMY
Clinical and Molecular Hepatology 2016;22(2):212-218
Laparoscopic liver resection (LLR) is becoming widely accepted for the treatment of hepatocellular carcinoma (HCC). Laparoscopic left lateral sectionectomy and minor laparoscopic liver resection are now considered standard approaches, especially for tumors located in the anterolateral segments of the liver. Laparoscopic left lateral sectionectomy in adult donors is also gaining acceptance for child liver transplantation in many centers. Major LLRs, including left hepatectomy and right hepatectomy, have been recently attempted. Laparoscopic donor hepatectomy is becoming more popular owing to increasing demand from young living donors who appreciate its minimal invasiveness and excellent cosmetic outcomes. Several centers have performed total laparoscopic donor right hepatectomy in adult-to-adult living donor liver transplantation. Many meta-analyses have shown that LLR is better than open liver resection in terms of short-term outcomes, principally cosmetic outcomes. Although no randomized control trials have compared LLR with open liver resection, the long-term oncologic outcomes were similar for both procedures in recent case-matched studies.
Carcinoma, Hepatocellular/complications/pathology/*surgery
;
Humans
;
Laparoscopy
;
Liver Cirrhosis/complications
;
Liver Neoplasms/pathology/*surgery
;
Neoplasm Recurrence, Local
;
Prognosis
8.A Case of Hepatocellular Carcinoma Combined with Liver Abscess.
Ju Ok YEOM ; Seung Bae YOON ; Jae Gyung KIM ; Jung Hwan OH ; Eun Jung JEON ; Jeong Jo JEONG ; Sang Wook CHOI ; Seong LEE
The Korean Journal of Gastroenterology 2009;53(6):378-382
Hepatocellular calcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer-related deaths worldwide. It is important to diagnose HCC exactly before management is attempted. But, the clinical presentations and radiologic findings of liver abscess, HCC, and metastatic tumor to the liver may be quite similar, and procedures such as serum tumor marker assay, computerized tomography, and ultrasonography of the liver cannot make a specific diagnosis. We report a case of HCC successfully diagnosed by surgery which was misconceived as liver abscess and not improved by medical treatment.
Carcinoma, Hepatocellular/complications/*diagnosis/pathology
;
Humans
;
Liver/ultrasonography
;
Liver Abscess/complications/*diagnosis/pathology
;
Liver Neoplasms/complications/*diagnosis/pathology
;
Male
;
Middle Aged
;
Tomography, X-Ray Computed
9.Surgical treatment of hepatocellular carcinoma with tumor thrombus in the inferior vena cava.
Yi WANG ; Han CHEN ; Meng-chao WU ; Yan-fu SUN ; Chuan LIN ; Xiao-qing JIANG ; Gong-tian WEI
Chinese Journal of Surgery 2003;41(3):165-168
OBJECTIVETo clarify the proper surgical procedure of treating hepatocellular carcinoma (HCC) with a tumor thrombus in the inferior vena cava (IVC).
METHODSFour patients with HCC with a tumor thrombus in the IVC underwent hepatectomy and thrombectomy. Following hepatectomy, tumor thrombus was removed by incising the wall of the IVC in 3 patients and from the hepatic vein in one patient. The 3 patients underwent thrombectomy under either hepatic vascular exclusion (HVE) or Satinsky's vascular clamping.
RESULTSAll the operations were successful without operative death and major complications. The postoperative course was uneventful in 3 patients and pleural effusion occurred in one patient who needed thoracentesis. Follow-up showed 3 patients died after 30, 10 and 14 months, respectively, and one patient is alive for 7 months.
CONCLUSIONSHCC with tumor thrombus in the IVC is operable and the proper procedure is hepatectomy plus thrombectomy.
Carcinoma, Hepatocellular ; complications ; surgery ; Humans ; Liver Neoplasms ; complications ; surgery ; Male ; Middle Aged ; Neoplastic Cells, Circulating ; Vena Cava, Inferior ; pathology